Latest Ratios: P/E Ratio -45.2x · EV/EBITDA N/A · ROE -24.7%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.8B | $1.4B | $326M | $294M | $410M | $359M | $227M | $8M | $5M | $14M | $26M |
| Enterprise Value | $5.8B | $1.3B | $265M | $257M | $368M | $306M | $178M | $-793811 | $-2037883 | $5M | $18M |
| P/E Ratio → | -45.20 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 9.31 | 2.93 | 0.85 | 7.94 | 9.83 | 7.03 | 4.87 | 0.99 | 0.76 | 1.37 | 1.16 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.7% | -24.7% | -39.9% | -13.6% | -21.4% | -39.6% | -36.0% | -80.4% | -97.3% | -113.9% | -54.6% |
| ROA | -23.8% | -23.8% | -38.6% | -13.2% | -20.3% | -36.7% | -33.0% | -71.4% | -82.7% | -100.0% | -51.2% |
| ROIC | -24.5% | -24.5% | -41.1% | — | — | — | — | — | -1221.4% | -171.5% | -177.2% |
| ROCE | -28.5% | -28.5% | -41.9% | -18.4% | -21.1% | -39.3% | -35.8% | -85.2% | -99.4% | -115.1% | -55.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.16 | -1.00 | -1.01 | -1.04 | -1.05 | -1.10 | -1.10 | -0.85 | -0.33 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -56.03 | — | — | — | -1082.00 | -806.00 | — | — | — |
Net cash position: cash ($47M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 22.37 | 22.37 | 28.89 | 59.01 | 37.72 | 15.56 | 14.28 | 9.16 | 8.55 | 5.94 | 8.95 |
| Quick Ratio | 22.37 | 22.37 | 28.89 | 59.01 | 37.72 | 15.56 | 14.28 | 9.16 | 8.55 | 5.94 | 8.95 |
| Cash Ratio | 21.92 | 21.92 | 28.80 | 58.76 | 37.50 | 15.25 | 14.02 | 9.03 | 8.33 | 5.68 | 8.83 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $46M | $17M | $14M | $14M | $14M | $5M | $110102 | $64115 | $48293 | $41978 |
Includes 30+ ratios · 21 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORKA stock.
Oruka Therapeutics, Inc.'s current P/E ratio is -45.2x. This places it at the 50th percentile of its historical range.
Oruka Therapeutics, Inc.'s return on equity (ROE) is -24.7%. The historical average is -71.2%.
Based on historical data, Oruka Therapeutics, Inc. is trading at a P/E of -45.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Dilutive financing dependence risk
Multiples Not Meaningful for Pre-Revenue Stage
Based on reported figures, ORKA trades at a P/E of -49.43 and a P/B of 10.18, with EV/EBITDA and P/S unavailable, so earnings-based multiples offer little guidance while the book multiple signals the market is paying a steep premium over tangible net assets.
The negative P/E reflects a net loss rather than a comparable earnings base, so it cannot be benchmarked against peers such as REGN at 20.94 in any meaningful way. The P/B of 10.18 versus REGN at 3.32 and ARQT at 18.98 suggests the market is pricing ORKA's pipeline and platform optionality well above its book value, which may indicate a platform premium rather than current fundamentals. Investors should monitor how this premium holds as clinical data arrives and the equity base continues to expand through financing.
Returns Improving Slightly Off Deep Trough
According to recent SEC filings, ORKA's ROE moved from -65.7% in 2024Q2 to -4.3% in 2026Q3, while ROIC has hovered near -5% to -6%, a pattern that reflects a rapidly enlarged equity base rather than improving operating economics.
The apparent convergence of ROE toward zero is largely mechanical, since equity grew from a small base to roughly $1.2B while losses expanded in absolute terms. ROIC remaining negative in the mid-single digits suggests capital is being deployed into clinical development without yet generating returns, which is expected for the stage. The improvement in ROE should therefore not be read as compounding; it may simply reflect the denominator effect of recent equity raises.
Minimal Debt Keeps Leverage Risk Contained
As reported in financial statements, ORKA's debt-to-equity ratio sits at roughly 0.00 across recent quarters, with interest coverage unavailable, indicating that leverage is not the binding constraint on the balance sheet.
With total debt of about $2.9M against roughly $1.2B in equity, the capital structure is overwhelmingly equity-funded, which removes covenant and refinancing risk from the near-term picture. Interest coverage cannot be meaningfully computed given the absence of operating earnings. The more relevant balance sheet pressure is the funding requirement itself rather than debt service, which warrants monitoring as spending continues.
Current Ratio Strong but Cash Burn Dominates
Based on reported figures, ORKA's current ratio fell from 38.51 in 2026Q2 to 29.62 in 2026Q3 and the quick ratio mirrors it, yet a quarterly operating outflow near $44.3M suggests these high ratios may overstate durable liquidity.
The current and quick ratios are nearly identical, consistent with a balance sheet dominated by cash and short-term holdings with negligible inventory. The decline from the prior quarter indicates that current liabilities or cash consumption are rising faster than the liquid asset base in relative terms. Liquidity should be assessed against the burn rate rather than the ratio itself, since the current ratio alone does not reveal how many quarters of operations the cash balance can support.
Asset-Light Ratios Obscure Financing Dependence
The ratio most commonly misapplied to ORKA is the current ratio, which appears strong at 29.62 yet ignores the cumulative cash burn exceeding $260M across ten quarters that the company has funded largely through external capital.
Because ORKA carries almost no inventory or receivables, standard working-capital ratios such as the current ratio and DSO offer little insight into operating health and can create a misleadingly comfortable picture. A more informative lens is cash runway measured as cash divided by quarterly operating burn, which on reported figures is well under two quarters at the latest run rate. Investors should weigh this runway metric and the pace of dilution more heavily than headline liquidity ratios.